A citation-based method for searching scientific literature

Stefan Klek, Brandie Heald, Alex Milinovich, Ying Ni, Jame Abraham, Haider Mahdi, Bassam Estfan, Alok A Khorana, Brian J Bolwell, Petros Grivas, Davendra P S Sohal, Pauline Funchain. JNCI Cancer Spectr 2020
Times Cited: 2







List of co-cited articles
6 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes.
Michael F Walsh, Deborah I Ritter, Chimene Kesserwan, Dmitriy Sonkin, Debyani Chakravarty, Elizabeth Chao, Rajarshi Ghosh, Yelena Kemel, Gang Wu, Kristy Lee,[...]. Hum Mutat 2018
16
100

Pathogenic Germline Variants in 10,389 Adult Cancers.
Kuan-Lin Huang, R Jay Mashl, Yige Wu, Deborah I Ritter, Jiayin Wang, Clara Oh, Marta Paczkowska, Sheila Reynolds, Matthew A Wyczalkowski, Ninad Oak,[...]. Cell 2018
241
100

Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group.
D Mandelker, M Donoghue, S Talukdar, C Bandlamudi, P Srinivasan, M Vivek, S Jezdic, H Hanson, K Snape, A Kulkarni,[...]. Ann Oncol 2019
32
100

Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.
Kasmintan A Schrader, Donavan T Cheng, Vijai Joseph, Meera Prasad, Michael Walsh, Ahmet Zehir, Ai Ni, Tinu Thomas, Ryma Benayed, Asad Ashraf,[...]. JAMA Oncol 2016
161
100

A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal.
James X Sun, Yuting He, Eric Sanford, Meagan Montesion, Garrett M Frampton, Stéphane Vignot, Jean-Charles Soria, Jeffrey S Ross, Vincent A Miller, Phil J Stephens,[...]. PLoS Comput Biol 2018
88
100

Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
Diana Mandelker, Liying Zhang, Yelena Kemel, Zsofia K Stadler, Vijai Joseph, Ahmet Zehir, Nisha Pradhan, Angela Arnold, Michael F Walsh, Yirong Li,[...]. JAMA 2017
185
100


Physician interpretation of variants of uncertain significance.
Sarah K Macklin, Jessica L Jackson, Paldeep S Atwal, Stephanie L Hines. Fam Cancer 2019
25
50


Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study.
Joanne Armstrong, Michele Toscano, Nancy Kotchko, Sue Friedman, Marc D Schwartz, Katherine S Virgo, Kristian Lynch, James E Andrews, Claudia X Aguado Loi, Joseph E Bauer,[...]. JAMA Oncol 2015
78
50

Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype.
Sarah L Sawyer, Lei Tian, Marketta Kähkönen, Jeremy Schwartzentruber, Martin Kircher, Jacek Majewski, David A Dyment, A Micheil Innes, Kym M Boycott, Lisa A Moreau,[...]. Cancer Discov 2015
191
50

ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.
Amanda B Spurdle, Sue Healey, Andrew Devereau, Frans B L Hogervorst, Alvaro N A Monteiro, Katherine L Nathanson, Paolo Radice, Dominique Stoppa-Lyonnet, Sean Tavtigian, Barbara Wappenschmidt,[...]. Hum Mutat 2012
181
50

Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.
S V Tavtigian, A M Deffenbaugh, L Yin, T Judkins, T Scholl, P B Samollow, D de Silva, A Zharkikh, A Thomas. J Med Genet 2006
473
50

Limited family structure and BRCA gene mutation status in single cases of breast cancer.
Jeffrey N Weitzel, Veronica I Lagos, Carey A Cullinane, Patricia J Gambol, Julie O Culver, Kathleen R Blazer, Melanie R Palomares, Katrina J Lowstuter, Deborah J MacDonald. JAMA 2007
130
50

A breast cancer prediction model incorporating familial and personal risk factors.
Jonathan Tyrer, Stephen W Duffy, Jack Cuzick. Stat Med 2004
648
50

Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
Douglas K Owens, Karina W Davidson, Alex H Krist, Michael J Barry, Michael Cabana, Aaron B Caughey, Chyke A Doubeni, John W Epling, Martha Kubik, C Seth Landefeld,[...]. JAMA 2019
107
50

Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer.
Karin Kast, Kerstin Rhiem, Barbara Wappenschmidt, Eric Hahnen, Jan Hauke, Britta Bluemcke, Verena Zarghooni, Natalie Herold, Nina Ditsch, Marion Kiechle,[...]. J Med Genet 2016
75
50

Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results.
Sharon E Plon, Diana M Eccles, Douglas Easton, William D Foulkes, Maurizio Genuardi, Marc S Greenblatt, Frans B L Hogervorst, Nicoline Hoogerbrugge, Amanda B Spurdle, Sean V Tavtigian. Hum Mutat 2008
542
50

BRCA1/2 mutations are not a common cause of malignant melanoma in the Polish population.
Tadeusz Dębniak, Rodney J Scott, Bohdan Górski, Bartłomiej Masojć, Andrzej Kram, Romuald Maleszka, Cezary Cybulski, Katarzyna Paszkowska-Szczur, Aniruddh Kashyap, Dawid Murawa,[...]. PLoS One 2018
5
50

Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board.
W Brian Dalton, Patrick M Forde, Hyunseok Kang, Roisin M Connolly, Vered Stearns, Christopher D Gocke, James R Eshleman, Jennifer Axilbund, Dana Petry, Cindy Geoghegan,[...]. JCO Precis Oncol 2017
27
50

Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.
Christine Fischer, Karoline Kuchenbäcker, Christoph Engel, Silke Zachariae, Kerstin Rhiem, Alfons Meindl, Nils Rahner, Nicola Dikow, Hansjörg Plendl, Irmgard Debatin,[...]. J Med Genet 2013
49
50

Homologous recombination in DNA repair and DNA damage tolerance.
Xuan Li, Wolf-Dietrich Heyer. Cell Res 2008
440
50

Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2.
David E Goldgar, Douglas F Easton, Amie M Deffenbaugh, Alvaro N A Monteiro, Sean V Tavtigian, Fergus J Couch. Am J Hum Genet 2004
274
50

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.
Mary B Daly, Robert Pilarski, Matthew B Yurgelun, Michael P Berry, Saundra S Buys, Patricia Dickson, Susan M Domchek, Ahmed Elkhanany, Susan Friedman, Judy E Garber,[...]. J Natl Compr Canc Netw 2020
93
50

BRCA1 and BRCA2 mutations in a population-based study of male breast cancer.
Victoria M Basham, Julian M Lipscombe, Joanna M Ward, Simon A Gayther, Bruce A J Ponder, Douglas F Easton, Paul D P Pharoah. Breast Cancer Res 2002
103
50

The landscape of genomic alterations across childhood cancers.
Susanne N Gröbner, Barbara C Worst, Joachim Weischenfeldt, Ivo Buchhalter, Kortine Kleinheinz, Vasilisa A Rudneva, Pascal D Johann, Gnana Prakash Balasubramanian, Maia Segura-Wang, Sebastian Brabetz,[...]. Nature 2018
436
50

Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours.
Xiaotu Ma, Yu Liu, Yanling Liu, Ludmil B Alexandrov, Michael N Edmonson, Charles Gawad, Xin Zhou, Yongjin Li, Michael C Rusch, John Easton,[...]. Nature 2018
259
50

Precision oncology based on omics data: The NCT Heidelberg experience.
Peter Horak, Barbara Klink, Christoph Heining, Stefan Gröschel, Barbara Hutter, Martina Fröhlich, Sebastian Uhrig, Daniel Hübschmann, Matthias Schlesner, Roland Eils,[...]. Int J Cancer 2017
63
50

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
A G Waks, O Cohen, B Kochupurakkal, D Kim, C E Dunn, J Buendia Buendia, S Wander, K Helvie, M R Lloyd, L Marini,[...]. Ann Oncol 2020
24
50

Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood.
Betsy Hirsch, Akiko Shimamura, Lisa Moreau, Shari Baldinger, Maha Hag-alshiekh, Bruce Bostrom, Susan Sencer, Alan D D'Andrea. Blood 2004
119
50

Clinical validity assessment of genes frequently tested on hereditary breast and ovarian cancer susceptibility sequencing panels.
Kristy Lee, Bryce A Seifert, Hermela Shimelis, Rajarshi Ghosh, Stephanie B Crowley, Natalie J Carter, Kurston Doonanco, A Katherine Foreman, Deborah I Ritter, Sharisse Jimenez,[...]. Genet Med 2019
24
50

BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors.
Andrew Lee, Nasim Mavaddat, Amber N Wilcox, Alex P Cunningham, Tim Carver, Simon Hartley, Chantal Babb de Villiers, Angel Izquierdo, Jacques Simard, Marjanka K Schmidt,[...]. Genet Med 2019
118
50

Discriminating somatic and germline mutations in tumor DNA samples without matching normals.
Saskia Hiltemann, Guido Jenster, Jan Trapman, Peter van der Spek, Andrew Stubbs. Genome Res 2015
42
50

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
Tom Walsh, Silvia Casadei, Ming K Lee, Christopher C Pennil, Alex S Nord, Anne M Thornton, Wendy Roeb, Kathy J Agnew, Sunday M Stray, Anneka Wickramanayake,[...]. Proc Natl Acad Sci U S A 2011
564
50

Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification.
Michael T Parsons, Emma Tudini, Hongyan Li, Eric Hahnen, Barbara Wappenschmidt, Lidia Feliubadaló, Cora M Aalfs, Simona Agata, Kristiina Aittomäki, Elisa Alducci,[...]. Hum Mutat 2019
42
50

Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer.
Barbara Wappenschmidt, Jan Hauke, Ulrike Faust, Dieter Niederacher, Lisa Wiesmüller, Gunnar Schmidt, Evi Groß, Andrea Gehrig, Christian Sutter, Juliane Ramser,[...]. Geburtshilfe Frauenheilkd 2020
2
50

ClinGen--the Clinical Genome Resource.
Heidi L Rehm, Jonathan S Berg, Lisa D Brooks, Carlos D Bustamante, James P Evans, Melissa J Landrum, David H Ledbetter, Donna R Maglott, Christa Lese Martin, Robert L Nussbaum,[...]. N Engl J Med 2015
482
50

Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients.
Magdalena Koczkowska, Natalia Krawczynska, Maciej Stukan, Alina Kuzniacka, Izabela Brozek, Marcin Sniadecki, Jaroslaw Debniak, Dariusz Wydra, Wojciech Biernat, Piotr Kozlowski,[...]. Cancers (Basel) 2018
17
50

Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches.
Lucia Guidugli, Hermela Shimelis, David L Masica, Vernon S Pankratz, Gary B Lipton, Namit Singh, Chunling Hu, Alvaro N A Monteiro, Noralane M Lindor, David E Goldgar,[...]. Am J Hum Genet 2018
34
50

Accelerating Discovery of Functional Mutant Alleles in Cancer.
Matthew T Chang, Tripti Shrestha Bhattarai, Alison M Schram, Craig M Bielski, Mark T A Donoghue, Philip Jonsson, Debyani Chakravarty, Sarah Phillips, Cyriac Kandoth, Alexander Penson,[...]. Cancer Discov 2018
117
50

BRCA in breast cancer: ESMO Clinical Practice Guidelines.
J Balmaña, O Díez, I T Rubio, F Cardoso. Ann Oncol 2011
114
50

Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohort.
Kerstin Rhiem, Hans-Joachim Bücker-Nott, Martin Hellmich, Holger Fischer, Beyhan Ataseven, Christine Dittmer-Grabowski, Kunibert Latos, Volker Pelzer, Manuela Seifert, Andrea Schmidt,[...]. Breast J 2019
8
50

Alternative splicing and ACMG-AMP-2015-based classification of PALB2 genetic variants: an ENIGMA report.
Irene Lopez-Perolio, Raphaël Leman, Raquel Behar, Vanessa Lattimore, John F Pearson, Laurent Castéra, Alexandra Martins, Dominique Vaur, Nicolas Goardon, Grégoire Davy,[...]. J Med Genet 2019
9
50

A method and server for predicting damaging missense mutations.
Ivan A Adzhubei, Steffen Schmidt, Leonid Peshkin, Vasily E Ramensky, Anna Gerasimova, Peer Bork, Alexey S Kondrashov, Shamil R Sunyaev. Nat Methods 2010
50

Germline Mutations in Cancer Predisposition Genes are Frequent in Sporadic Sarcomas.
Sock Hoai Chan, Weng Khong Lim, Nur Diana Binte Ishak, Shao-Tzu Li, Wei Lin Goh, Gek San Tan, Kiat Hon Lim, Melissa Teo, Cedric Ng Chuan Young, Simeen Malik,[...]. Sci Rep 2017
28
50

Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system.
Angeliki Delimitsou, Florentia Fostira, Despoina Kalfakakou, Paraskevi Apostolou, Irene Konstantopoulou, Christos Kroupis, Athanasios G Papavassiliou, Zdenek Kleibl, Efstratios Stratikos, Gerassimos E Voutsinas,[...]. Hum Mutat 2019
10
50

Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award.
Mary-Claire King, Ephrat Levy-Lahad, Amnon Lahad. JAMA 2014
172
50

Personalized genomic analyses for cancer mutation discovery and interpretation.
Siân Jones, Valsamo Anagnostou, Karli Lytle, Sonya Parpart-Li, Monica Nesselbush, David R Riley, Manish Shukla, Bryan Chesnick, Maura Kadan, Eniko Papp,[...]. Sci Transl Med 2015
236
50

A Multiplex Homology-Directed DNA Repair Assay Reveals the Impact of More Than 1,000 BRCA1 Missense Substitution Variants on Protein Function.
Lea M Starita, Muhtadi M Islam, Tapahsama Banerjee, Aleksandra I Adamovich, Justin Gullingsrud, Stanley Fields, Jay Shendure, Jeffrey D Parvin. Am J Hum Genet 2018
50
50

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.
Nicolai J Birkbak, Zhigang C Wang, Ji-Young Kim, Aron C Eklund, Qiyuan Li, Ruiyang Tian, Christian Bowman-Colin, Yang Li, April Greene-Colozzi, J Dirk Iglehart,[...]. Cancer Discov 2012
219
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.